|Denaro||63,18 x 1400|
|Lettera||63,30 x 800|
|Min-Max giorno||62,13 - 63,59|
|Intervallo di 52 settimane||56,56 - 85,97|
|Beta (5 anni mensile)||0,53|
|Rapporto PE (ttm)||62,89|
|Prossima data utili||02 feb 2021 - 08 feb 2021|
|Rendimento e dividendo (forward)||2,72 (4,29%)|
|Data ex dividendo||14 dic 2020|
|Stima target 1A||72,46|
The U.S. drugmaker Gilead Sciences revised its full-year 2020 profit guidance as the second wave of coronavirus infections boosted the demand of Remdesivir, an antiviral agent that scientists initially designed to treat Ebola, also, beneficial for COVID-19 treatment.
Gilead Sciences said that the U.S. Food and Drug Administration has approved the antiviral drug remdesivir for the COVID-19 treatment, sending its shares up about 6% in pre-market on Friday.
Gilead Sciences Inc, an American biopharmaceutical company that researches, develops and commercializes drugs, announced to acquire a pharmaceutical company Immunomedics Inc for $21 billion or $88.00 per share in cash, a move that will help strengthen its drugs portfolio for cancer.